Gerberding and a representative from Moderna did not comment on the price they have in mind for their vaccines at the hearing, which focused on efforts to develop a safe, effective and widely accessible vaccine against COVID-19, which has claimed 600,000 lives globally.
Mene Pangalos, executive vice president of biopharmaceutical research and development for AstraZeneca, a British-Swedish multinational pharmaceutical and biopharmaceutical company, said that a vaccine for coronavirus could be available "anytime from September".
Russian Federation said on 20 July that it hopes to complete trials of a coronavirus vaccine in August and produce 200 million doses with foreign partners by the end of the year.
The University of Oxford have trialled it on a group of 1,077 people and the results are in. And to keep following these individuals and start trials elsewhere.
The US government has already invested $1.2 billion to secure 300 million doses of the vaccine.
Phase 3 will need to prove the vaccine works in the real world, CBS explains.
Valneva, which has a manufacturing base at Livingston in Scotland, is behind one of two coronavirus vaccine partnerships announced by the United Kingdom government earlier this week.
The University of Oxford with pharmaceutical firm AstraZeneca has developed a vaccine that shows potential in triggering the immune response against COVID-19.
The company has also announced that it expects to have results and have doses prepared in the coming months.
British government Business Secretary Alok Sharma called the results "extremely encouraging, taking us one step closer to finding a successful vaccine to protect millions in the United Kingdom and across the world", per CBS News.
Do you think the federal government should standardize the price of the COVID-19 vaccine, or set an MSRP?
If the approvals are in place and trials are completed successfully, then lot of companies will manufacture the vaccine and India will be the largest producer of the COVID-19 vaccine in the world, he added.
"We show that a single dose of ChAdOx1 nCoV-19 elicits an increase in spike-specific Antibodies by day 28 and neutralising antibody in all participants after a booster dose".